Mr. Mark Upsdell reports

RAPID DOSE THERAPEUTICS (DOSE) (RDTCF) AND BODHI HEALTH EXPAND DISTRIBUTION AND SALES OF CURCUWIN QUICKSTRIP CURCUMIN ACROSS CANADA

Rapid Dose Therapeutics Corp. and Ontario-based Bodhi Health Inc. have expanded their co-ordinated distribution, sales and market development efforts for Bodhi Health sublingual curcumin, manufactured using Rapid Dose's proprietary QuickStrip oral thin-film technology and the patented CurcuWIN curcumin formulation, with over 300,000 units sold to date.

Rapid Dose produces the oral thin-film product while Bodhi Health serves as the Canadian distributor and North American supplier of the finished CurcuWIN QuickStrip product. The product combines two differentiated technologies: the patented CurcuWIN curcumin formulation and Rapid Dose's proprietary QuickStrip oral thin-film delivery platform. Under the companies' commercial arrangement, the CurcuWIN formulation is available in an oral thin-film format exclusively through Rapid Dose.

Unlike conventional capsules and tablets that must be swallowed, the QuickStrip format dissolves conveniently in the mouth and delivers directly into the blood stream. Companies believe this combination offers a compelling and highly differentiated option for consumers seeking natural support for joint health, inflammation-related discomfort and active lifestyles.

"Curcumin has been recognized for years for its potential health benefits, but delivering it in a discreet, convenient and effective format has remained an important challenge," said Mark Upsdell, chief executive officer of Rapid Dose. "Published human research evaluating the CurcuWIN formulation has demonstrated enhanced curcuminoid absorption compared with conventional, unformulated curcumin. By combining this scientifically studied formulation with our proprietary QuickStrip oral thin-film platform, we believe we have created a highly differentiated product that supports our long-term commercial growth strategy."

Bodhi Health and Rapid Dose are expanding their commercial initiatives in response to what the companies describe as increasing demand from retailers, health practitioners and consumers. The product is currently available through a growing Canadian network that includes Calgary Co-op, Nature's Emporium, Good Health Mart and numerous independent natural health retailers.

A significant portion of the product's growth is also being generated through health practitioner offices across Canada, including chiropractors, sports therapists, rehabilitation professionals and other practitioners working with active individuals and consumers experiencing joint or muscle discomfort. Bodhi Health is simultaneously developing a rapidly growing direct-to-consumer business, allowing Canadians to purchase the product directly while learning more about its formulation, oral thin-film delivery format and suggested use.

"The relationship between Rapid Dose and Bodhi Health demonstrates what can be achieved when innovative manufacturing technology is paired with a focused and knowledgeable distribution organization," Mr. Upsdell continued. "Bodhi understands the natural health marketplace, has strong relationships with retailers and practitioners, and has done an excellent job communicating the distinctive qualities of this product. We are extremely pleased with the relationship and look forward to supporting Bodhi as it expands distribution throughout Canada and across North America."

Bodhi Health will also attend CHFA NOW Toronto, being held at Exhibition Place from Sept. 25 to Sept. 27, 2026. The event brings together participants from across Canada's natural, organic and wellness industry, and will provide Bodhi Health with opportunities to meet retailers, distributors, practitioners and other prospective commercial partners. The companies intend to use the event to strengthen existing relationships, introduce the CurcuWIN QuickStrip product to new accounts, and advance discussions regarding further Canadian and North American distribution opportunities.

Scientific background

Published scientific research supporting the product's formulation includes a randomized, double-blind human crossover study published in Nutrition Journal, which found that the CurcuWIN formulation generated approximately 45.9 times greater total curcuminoid absorption than unformulated curcumin. Additional randomized research involving CurcuWIN has reported encouraging results in selected measures of exercise recovery and soreness while systematic reviews of curcumin and turmeric extracts have identified potential benefits for inflammatory biomarkers, joint discomfort and physical function. These studies evaluated CurcuWIN or other curcumin formulations, and were not clinical trials of the finished CurcuWIN QuickStrip product but are accurately presenting the outcomes of the active.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film that can be infused with a broad range of active ingredients, including nutraceuticals, pharmaceuticals and vaccines that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

We seek Safe Harbor.